Health Catalyst price target raised to $12 from $11 at Piper Sandler

Piper Sandler raised the firm’s price target on Health Catalyst to $12 from $11 and keeps an Overweight rating on the shares. The analyst believes that “improving end market and transformational commercial strategy” will lead to “10% adjusted EBITDA margins and double-digit revenue growth in 2025,” and the firm is a buy of Health Catalyst into the new year.